VRC 016: A Phase 1b Open-Label, Randomized Clinical Trial to Evaluate Early Innate and Adaptive Immune Responses to the Investigational ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2014

ABSTRACT

Background: The primary focus of the Vaccine Research Center (VRC) at the NIH is to develop vaccines for HIV/AIDS. The main purpose of this study is to look in detail at the body s immune response to two experimental HIV vaccines currently in development at the VRC. One is known as the rAd5 vaccine and the other is known as the DNA vaccine. These vaccines are made with pieces of manufactured DNA. They do not contain live or killed HIV. It is impossible for study vaccines to give you HIV and they cannot cause you to give HIV to someone else. Both of these experimental vaccines have been given to people before in other research studies. They have not been approved for treating or preventing HIV infection. Purpose: The main purpose of this study is to look in detail at the body s immune responses after the experimental HIV vaccines are given and to assess safety of the study vaccines. Eligibility: Healthy volunteers between the ages of 18 and 50 who are not infected with HIV and who meet the eligibility requirements. Design: Participants will be screened with a medical history (including questions about sexual history and drug use), physical exam, and blood tests. The study will have two groups: One group will receive one injection of the rAd5 vaccine, and have 8 clinic visits over 3 months. The second group will have three injections of the DNA vaccine, one injection of the rAd5 vaccine, and have 12 clinic visits over 6 months. All participants will be asked to provide blood and body fluid samples for testing during the study. Payment for participation will be provided. Detailed Description Study Design: This is a hypothesis-generating descriptive study to evaluate the kinetics and pattern of early innate and adaptive immune responses to the VRC recombinant adenoviral vector serotype 5 vaccine, VRC-HIVADV014-00-VP (rAd5). The rAd5 vaccine has been previously administered to more than 1000 study subjects and characterized as safe and immunogenic. A difference in the pattern of vaccine antigen-specific immune responses observed when rAd5 is given as a single agent compared to after priming by a 6-plasmid DNA vaccine, VRCHIVDNA016-00-VP, has previously been reported. This study will randomize vaccine-naive subjects to receive a single injection of rAd5 or to the DNA primerAd5 boost regimen that is now in a large Phase II study. Collection of blood, rectal, oral and genital specimens for characterization of early innate and adaptive immune responses will follow receipt of rAd5. The hypothesis is that the pattern of early innate and adaptive immune responses elicited by the rAd5 vaccine administered after priming with DNA vaccine will be distinctly different from the pattern elicited when rAd5 is administered as a single agent. The primary objectives are to describe the kinetics and pattern of early innate and adaptive immune responses that occur in blood samples early after administration of rAd5 vaccine alone and after administration following 3 DNA prime injections. Secondary and exploratory objectives are related safety, as well as the pattern of immune responses in mucosal samples and in blood samples. Product Description: VRC-HIVDNA016-00-VP [6-plasmid DNA vaccine] is composed of 6 closed, circular DNA plasmids that encode for HIV-1 Gag, Pol and Nef proteins (from clade B) and Env glycoproteins from clade A, clade B, and clade C, which are combined in equal proportions. All injections will be at 4 mg dose in a 1 mL volume administered intramuscularly (IM) by Biojector (registered trademark) into deltoid muscle. VRC-HIVADV014-00-VP (rAd5 vaccine) is composed of 4 recombinant nonreplicating adenoviral vectors that encode for HIV-1 Gag/Pol polyproteins (from clade B) and Env glycoproteins from clade A, clade B, and clade C, which are combined in a 3:1:1:1 ratio, respectively, in a final formulation buffer (FFB). All injections will be at 10(10) PU dose in a 1 mL volume administered IM by needle and syringe into deltoid muscle. Subjects: The study target accrual is at least 20 subjects who complete collection of blood, oral, rectal and genital specimens through 2 weeks after the rAd5 vaccination. To account for potential discontinuations from the study, enrollment may include up to 36 HIV-uninfected adults, ages 18-50 years old that are HIV vaccine-naive and adenovirus serotype 5 (Ad5) antibody negative at screening; males must be fully circumcised. Study Plan: Subjects will be randomized at a 1:1 ratio to receive a single injection of rAd5 or the DNA prime-rAd5 boost schedule and will be stratified by gender to achieve approximately equal distribution of each gender into the two vaccination schedules. Subjects randomized to Group 1 may receive the vaccination on enrollment day or schedule the day of vaccination to occur within 6 weeks followed by the expected 24 hours in the inpatient unit and day 3 post-vaccination sample collections for the frequent sampling that will immediately ensue according to the sample collection schedule. Subjects randomized to Group 2 will receive the first of three DNA vaccinations and schedule projected dates for the subsequent injections and timepoints with intensive sample collection schedules. Due to the need to commit to about 3 days of disruption in normal daily activities, starting with the day of rAd5 vaccination on either schedule, flexibility in scheduling of the rAd5 vaccination is included in the protocol plan. Subjects from both groups will be admitted to the NIH Clinical Center overnight for the first 24 hours following vaccination with rAd5. On the rAd5 vaccination day, peripheral blood samples will be collected for serum, plasma and peripheral blood mononuclear cells at seven target time points in the first 24 hours as follows: pre-injection and post-injection hours 1, 3, 6, 12, 18 and 24; then days 3, 5, 7, 14 and 28 post-rAd5 vaccine. Mucosal sampling will occur on day 14 after rAd5 vaccine. This will include buccal mucosa, rectal secretions, cervical secretions (from women) and semen samples (from men). There will be a blood collection to assess innate immunity following the 3rd DNA vaccination in Group 2 with blood draws at pre-injection and at post-injection hours 1, 3, 6 and 18. The safety of vaccinations and the research plan will be monitored by a protocol safety review team. Study Duration: Subjects will be followed in the clinic through 12 weeks after last study injection and contacted for long term follow-up 12 weeks later and then every 48 weeks through Study Week 144. More... »

URL

https://clinicaltrials.gov/show/NCT01386489

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background: The primary focus of the Vaccine Research Center (VRC) at the NIH is to develop vaccines for HIV/AIDS. The main purpose of this study is to look in detail at the body s immune response to two experimental HIV vaccines currently in development at the VRC. One is known as the rAd5 vaccine and the other is known as the DNA vaccine. These vaccines are made with pieces of manufactured DNA. They do not contain live or killed HIV. It is impossible for study vaccines to give you HIV and they cannot cause you to give HIV to someone else. Both of these experimental vaccines have been given to people before in other research studies. They have not been approved for treating or preventing HIV infection. Purpose: The main purpose of this study is to look in detail at the body s immune responses after the experimental HIV vaccines are given and to assess safety of the study vaccines. Eligibility: Healthy volunteers between the ages of 18 and 50 who are not infected with HIV and who meet the eligibility requirements. Design: Participants will be screened with a medical history (including questions about sexual history and drug use), physical exam, and blood tests. The study will have two groups: One group will receive one injection of the rAd5 vaccine, and have 8 clinic visits over 3 months. The second group will have three injections of the DNA vaccine, one injection of the rAd5 vaccine, and have 12 clinic visits over 6 months. All participants will be asked to provide blood and body fluid samples for testing during the study. Payment for participation will be provided.\n\nDetailed Description\nStudy Design: This is a hypothesis-generating descriptive study to evaluate the kinetics and pattern of early innate and adaptive immune responses to the VRC recombinant adenoviral vector serotype 5 vaccine, VRC-HIVADV014-00-VP (rAd5). The rAd5 vaccine has been previously administered to more than 1000 study subjects and characterized as safe and immunogenic. A difference in the pattern of vaccine antigen-specific immune responses observed when rAd5 is given as a single agent compared to after priming by a 6-plasmid DNA vaccine, VRCHIVDNA016-00-VP, has previously been reported. This study will randomize vaccine-naive subjects to receive a single injection of rAd5 or to the DNA primerAd5 boost regimen that is now in a large Phase II study. Collection of blood, rectal, oral and genital specimens for characterization of early innate and adaptive immune responses will follow receipt of rAd5. The hypothesis is that the pattern of early innate and adaptive immune responses elicited by the rAd5 vaccine administered after priming with DNA vaccine will be distinctly different from the pattern elicited when rAd5 is administered as a single agent. The primary objectives are to describe the kinetics and pattern of early innate and adaptive immune responses that occur in blood samples early after administration of rAd5 vaccine alone and after administration following 3 DNA prime injections. Secondary and exploratory objectives are related safety, as well as the pattern of immune responses in mucosal samples and in blood samples. Product Description: VRC-HIVDNA016-00-VP [6-plasmid DNA vaccine] is composed of 6 closed, circular DNA plasmids that encode for HIV-1 Gag, Pol and Nef proteins (from clade B) and Env glycoproteins from clade A, clade B, and clade C, which are combined in equal proportions. All injections will be at 4 mg dose in a 1 mL volume administered intramuscularly (IM) by Biojector (registered trademark) into deltoid muscle. VRC-HIVADV014-00-VP (rAd5 vaccine) is composed of 4 recombinant nonreplicating adenoviral vectors that encode for HIV-1 Gag/Pol polyproteins (from clade B) and Env glycoproteins from clade A, clade B, and clade C, which are combined in a 3:1:1:1 ratio, respectively, in a final formulation buffer (FFB). All injections will be at 10(10) PU dose in a 1 mL volume administered IM by needle and syringe into deltoid muscle. Subjects: The study target accrual is at least 20 subjects who complete collection of blood, oral, rectal and genital specimens through 2 weeks after the rAd5 vaccination. To account for potential discontinuations from the study, enrollment may include up to 36 HIV-uninfected adults, ages 18-50 years old that are HIV vaccine-naive and adenovirus serotype 5 (Ad5) antibody negative at screening; males must be fully circumcised. Study Plan: Subjects will be randomized at a 1:1 ratio to receive a single injection of rAd5 or the DNA prime-rAd5 boost schedule and will be stratified by gender to achieve approximately equal distribution of each gender into the two vaccination schedules. Subjects randomized to Group 1 may receive the vaccination on enrollment day or schedule the day of vaccination to occur within 6 weeks followed by the expected 24 hours in the inpatient unit and day 3 post-vaccination sample collections for the frequent sampling that will immediately ensue according to the sample collection schedule. Subjects randomized to Group 2 will receive the first of three DNA vaccinations and schedule projected dates for the subsequent injections and timepoints with intensive sample collection schedules. Due to the need to commit to about 3 days of disruption in normal daily activities, starting with the day of rAd5 vaccination on either schedule, flexibility in scheduling of the rAd5 vaccination is included in the protocol plan. Subjects from both groups will be admitted to the NIH Clinical Center overnight for the first 24 hours following vaccination with rAd5. On the rAd5 vaccination day, peripheral blood samples will be collected for serum, plasma and peripheral blood mononuclear cells at seven target time points in the first 24 hours as follows: pre-injection and post-injection hours 1, 3, 6, 12, 18 and 24; then days 3, 5, 7, 14 and 28 post-rAd5 vaccine. Mucosal sampling will occur on day 14 after rAd5 vaccine. This will include buccal mucosa, rectal secretions, cervical secretions (from women) and semen samples (from men). There will be a blood collection to assess innate immunity following the 3rd DNA vaccination in Group 2 with blood draws at pre-injection and at post-injection hours 1, 3, 6 and 18. The safety of vaccinations and the research plan will be monitored by a protocol safety review team. Study Duration: Subjects will be followed in the clinic through 12 weeks after last study injection and contacted for long term follow-up 12 weeks later and then every 48 weeks through Study Week 144.", 
    "endDate": "2014-03-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01386489", 
    "keywords": [
      "regimen", 
      "sample", 
      "final formulation", 
      "development", 
      "plasmid DNA", 
      "HIV infection", 
      "vaccine", 
      "descriptive study", 
      "protein", 
      "body", 
      "antibody", 
      "Innate Immunity", 
      "circular DNA", 
      "plasma", 
      "IM", 
      "Pliability", 
      "peripheral blood sample", 
      "Group 2", 
      "vaccine research", 
      "sexual history", 
      "pattern", 
      "inpatient unit", 
      "Live", 
      "disruption", 
      "piece", 
      "serotypes", 
      "VRC", 
      "age", 
      "volume", 
      "HIV/AIDS", 
      "randomized clinical trial", 
      "adult", 
      "adenoviral vector", 
      "injection", 
      "Hematologic Test", 
      "Adaptive Immunity", 
      "NIH", 
      "study plan", 
      "participation", 
      "study design", 
      "research plan", 
      "pol", 
      "exploratory", 
      "time point", 
      "specimen", 
      "HIV vaccine", 
      "eligibility requirement", 
      "Group 1", 
      "vaccination", 
      "receipt", 
      "Evaluate", 
      "study subject", 
      "randomize", 
      "Mass Screening", 
      "product", 
      "muscle", 
      "enrollment", 
      "Mouth Mucosa", 
      "physical exam", 
      "payment", 
      "woman", 
      "long term", 
      "serum", 
      "male", 
      "sample collection", 
      "safety", 
      "DNA vaccination", 
      "blood", 
      "peripheral blood mononuclear cell", 
      "single injection", 
      "eligibility", 
      "semen sample", 
      "primary objective", 
      "frequent sampling", 
      "discontinuation", 
      "NIH Clinical Center", 
      "difference", 
      "equal distribution", 
      "sampling", 
      "Organization and Administration", 
      "blood collection", 
      "innate and adaptive immune response", 
      "needle", 
      "review team", 
      "rAd5", 
      "fluid sample", 
      "healthy adult", 
      "men", 
      "timepoints", 
      "priming", 
      "post-injection", 
      "clade", 
      "Ad5", 
      "detail", 
      "syrinx", 
      "second group", 
      "primary focus", 
      "HIV-1 Gag", 
      "DNA vaccine", 
      "clinic", 
      "protocol", 
      "DNA", 
      "Phase II study", 
      "antigen-specific immune response", 
      "medical history", 
      "Vaccine Research Center", 
      "healthy volunteer", 
      "Gender Identity", 
      "someone", 
      "research study", 
      "Ambulatory Care", 
      "immune response", 
      "collection", 
      "complete collection", 
      "Appointment and Schedule", 
      "study target", 
      "polyprotein", 
      "blood sample", 
      "dose", 
      "single agent", 
      "last study", 
      "kinetics", 
      "equal proportion", 
      "label", 
      "HIV", 
      "drug use", 
      "study duration", 
      "glycoprotein", 
      "date", 
      "experimental vaccine", 
      "main purpose", 
      "recombinant adenoviral vector"
    ], 
    "name": "VRC 016: A Phase 1b Open-Label, Randomized Clinical Trial to Evaluate Early Innate and Adaptive Immune Responses to the Investigational HIV-1 Vaccines: VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP in Ad5 Seronegative Healthy Adults", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01386489"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00010.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419681.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1371/journal.pone.0009015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013116165"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.immuni.2010.09.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019947341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1742-4690-7-84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049858485", 
          "https://doi.org/10.1186/1742-4690-7-84"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01386489"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01386489'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01386489'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01386489'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01386489'


 

This table displays all metadata directly associated to this object as RDF triples.

163 TRIPLES      16 PREDICATES      151 URIs      141 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01386489 schema:about anzsrc-for:3103
2 schema:description Background: The primary focus of the Vaccine Research Center (VRC) at the NIH is to develop vaccines for HIV/AIDS. The main purpose of this study is to look in detail at the body s immune response to two experimental HIV vaccines currently in development at the VRC. One is known as the rAd5 vaccine and the other is known as the DNA vaccine. These vaccines are made with pieces of manufactured DNA. They do not contain live or killed HIV. It is impossible for study vaccines to give you HIV and they cannot cause you to give HIV to someone else. Both of these experimental vaccines have been given to people before in other research studies. They have not been approved for treating or preventing HIV infection. Purpose: The main purpose of this study is to look in detail at the body s immune responses after the experimental HIV vaccines are given and to assess safety of the study vaccines. Eligibility: Healthy volunteers between the ages of 18 and 50 who are not infected with HIV and who meet the eligibility requirements. Design: Participants will be screened with a medical history (including questions about sexual history and drug use), physical exam, and blood tests. The study will have two groups: <TAB>One group will receive one injection of the rAd5 vaccine, and have 8 clinic visits over 3 months. <TAB>The second group will have three injections of the DNA vaccine, one injection of the rAd5 vaccine, and have 12 clinic visits over 6 months. All participants will be asked to provide blood and body fluid samples for testing during the study. Payment for participation will be provided. Detailed Description Study Design: This is a hypothesis-generating descriptive study to evaluate the kinetics and pattern of early innate and adaptive immune responses to the VRC recombinant adenoviral vector serotype 5 vaccine, VRC-HIVADV014-00-VP (rAd5). The rAd5 vaccine has been previously administered to more than 1000 study subjects and characterized as safe and immunogenic. A difference in the pattern of vaccine antigen-specific immune responses observed when rAd5 is given as a single agent compared to after priming by a 6-plasmid DNA vaccine, VRCHIVDNA016-00-VP, has previously been reported. This study will randomize vaccine-naive subjects to receive a single injection of rAd5 or to the DNA primerAd5 boost regimen that is now in a large Phase II study. Collection of blood, rectal, oral and genital specimens for characterization of early innate and adaptive immune responses will follow receipt of rAd5. The hypothesis is that the pattern of early innate and adaptive immune responses elicited by the rAd5 vaccine administered after priming with DNA vaccine will be distinctly different from the pattern elicited when rAd5 is administered as a single agent. The primary objectives are to describe the kinetics and pattern of early innate and adaptive immune responses that occur in blood samples early after administration of rAd5 vaccine alone and after administration following 3 DNA prime injections. Secondary and exploratory objectives are related safety, as well as the pattern of immune responses in mucosal samples and in blood samples. Product Description: VRC-HIVDNA016-00-VP [6-plasmid DNA vaccine] is composed of 6 closed, circular DNA plasmids that encode for HIV-1 Gag, Pol and Nef proteins (from clade B) and Env glycoproteins from clade A, clade B, and clade C, which are combined in equal proportions. All injections will be at 4 mg dose in a 1 mL volume administered intramuscularly (IM) by Biojector (registered trademark) into deltoid muscle. VRC-HIVADV014-00-VP (rAd5 vaccine) is composed of 4 recombinant nonreplicating adenoviral vectors that encode for HIV-1 Gag/Pol polyproteins (from clade B) and Env glycoproteins from clade A, clade B, and clade C, which are combined in a 3:1:1:1 ratio, respectively, in a final formulation buffer (FFB). All injections will be at 10(10) PU dose in a 1 mL volume administered IM by needle and syringe into deltoid muscle. Subjects: The study target accrual is at least 20 subjects who complete collection of blood, oral, rectal and genital specimens through 2 weeks after the rAd5 vaccination. To account for potential discontinuations from the study, enrollment may include up to 36 HIV-uninfected adults, ages 18-50 years old that are HIV vaccine-naive and adenovirus serotype 5 (Ad5) antibody negative at screening; males must be fully circumcised. Study Plan: Subjects will be randomized at a 1:1 ratio to receive a single injection of rAd5 or the DNA prime-rAd5 boost schedule and will be stratified by gender to achieve approximately equal distribution of each gender into the two vaccination schedules. Subjects randomized to Group 1 may receive the vaccination on enrollment day or schedule the day of vaccination to occur within 6 weeks followed by the expected 24 hours in the inpatient unit and day 3 post-vaccination sample collections for the frequent sampling that will immediately ensue according to the sample collection schedule. Subjects randomized to Group 2 will receive the first of three DNA vaccinations and schedule projected dates for the subsequent injections and timepoints with intensive sample collection schedules. Due to the need to commit to about 3 days of disruption in normal daily activities, starting with the day of rAd5 vaccination on either schedule, flexibility in scheduling of the rAd5 vaccination is included in the protocol plan. Subjects from both groups will be admitted to the NIH Clinical Center overnight for the first 24 hours following vaccination with rAd5. On the rAd5 vaccination day, peripheral blood samples will be collected for serum, plasma and peripheral blood mononuclear cells at seven target time points in the first 24 hours as follows: pre-injection and post-injection hours 1, 3, 6, 12, 18 and 24; then days 3, 5, 7, 14 and 28 post-rAd5 vaccine. Mucosal sampling will occur on day 14 after rAd5 vaccine. This will include buccal mucosa, rectal secretions, cervical secretions (from women) and semen samples (from men). There will be a blood collection to assess innate immunity following the 3rd DNA vaccination in Group 2 with blood draws at pre-injection and at post-injection hours 1, 3, 6 and 18. The safety of vaccinations and the research plan will be monitored by a protocol safety review team. Study Duration: Subjects will be followed in the clinic through 12 weeks after last study injection and contacted for long term follow-up 12 weeks later and then every 48 weeks through Study Week 144.
3 schema:endDate 2014-03-01T00:00:00Z
4 schema:keywords Ad5
5 Adaptive Immunity
6 Ambulatory Care
7 Appointment and Schedule
8 DNA
9 DNA vaccination
10 DNA vaccine
11 Evaluate
12 Gender Identity
13 Group 1
14 Group 2
15 HIV
16 HIV infection
17 HIV vaccine
18 HIV-1 Gag
19 HIV/AIDS
20 Hematologic Test
21 IM
22 Innate Immunity
23 Live
24 Mass Screening
25 Mouth Mucosa
26 NIH
27 NIH Clinical Center
28 Organization and Administration
29 Phase II study
30 Pliability
31 VRC
32 Vaccine Research Center
33 adenoviral vector
34 adult
35 age
36 antibody
37 antigen-specific immune response
38 blood
39 blood collection
40 blood sample
41 body
42 circular DNA
43 clade
44 clinic
45 collection
46 complete collection
47 date
48 descriptive study
49 detail
50 development
51 difference
52 discontinuation
53 disruption
54 dose
55 drug use
56 eligibility
57 eligibility requirement
58 enrollment
59 equal distribution
60 equal proportion
61 experimental vaccine
62 exploratory
63 final formulation
64 fluid sample
65 frequent sampling
66 glycoprotein
67 healthy adult
68 healthy volunteer
69 immune response
70 injection
71 innate and adaptive immune response
72 inpatient unit
73 kinetics
74 label
75 last study
76 long term
77 main purpose
78 male
79 medical history
80 men
81 muscle
82 needle
83 participation
84 pattern
85 payment
86 peripheral blood mononuclear cell
87 peripheral blood sample
88 physical exam
89 piece
90 plasma
91 plasmid DNA
92 pol
93 polyprotein
94 post-injection
95 primary focus
96 primary objective
97 priming
98 product
99 protein
100 protocol
101 rAd5
102 randomize
103 randomized clinical trial
104 receipt
105 recombinant adenoviral vector
106 regimen
107 research plan
108 research study
109 review team
110 safety
111 sample
112 sample collection
113 sampling
114 second group
115 semen sample
116 serotypes
117 serum
118 sexual history
119 single agent
120 single injection
121 someone
122 specimen
123 study design
124 study duration
125 study plan
126 study subject
127 study target
128 syrinx
129 time point
130 timepoints
131 vaccination
132 vaccine
133 vaccine research
134 volume
135 woman
136 schema:name VRC 016: A Phase 1b Open-Label, Randomized Clinical Trial to Evaluate Early Innate and Adaptive Immune Responses to the Investigational HIV-1 Vaccines: VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP in Ad5 Seronegative Healthy Adults
137 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01386489
138 schema:sdDatePublished 2019-03-07T15:24
139 schema:sdLicense https://scigraph.springernature.com/explorer/license/
140 schema:sdPublisher N7a836933042140228dd8cc85e73088f4
141 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
142 https://www.grid.ac/institutes/grid.419681.3
143 schema:startDate 2011-06-01T00:00:00Z
144 schema:subjectOf sg:pub.10.1186/1742-4690-7-84
145 https://doi.org/10.1016/j.immuni.2010.09.011
146 https://doi.org/10.1371/journal.pone.0009015
147 schema:url https://clinicaltrials.gov/show/NCT01386489
148 sgo:license sg:explorer/license/
149 sgo:sdDataset clinical_trials
150 rdf:type schema:MedicalStudy
151 N7a836933042140228dd8cc85e73088f4 schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
154 rdf:type schema:DefinedTerm
155 sg:pub.10.1186/1742-4690-7-84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049858485
156 https://doi.org/10.1186/1742-4690-7-84
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/j.immuni.2010.09.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019947341
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1371/journal.pone.0009015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013116165
161 rdf:type schema:CreativeWork
162 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
163 https://www.grid.ac/institutes/grid.419681.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...